MAPT H1c — The Sub-haplotype That Amplifies Tauopathy Risk
Within the H1 haplotype of the MAPT gene — itself a well-established risk factor for neurodegenerative
diseases involving tau protein — there exists a finer level of genetic variation. The rs242557
variant tags the H1c sub-haplotype, a distinct subset of H1 that carries substantially elevated risk
for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to other H1
sub-haplotypes. This SNP adds resolution beyond the broad H1/H2 distinction captured by rs17649553,
identifying individuals within the H1 majority who face the highest tau-related risk.
The Mechanism
Unlike the H1/H2 distinction — driven by a 900kb chromosomal inversion — H1c is a sub-haplotype
within H1 defined by a specific combination of intronic variants including rs242557. The A allele at
rs242557 tags the H1c configuration, which is associated with altered transcriptional regulation of
the MAPT gene | The intronic variant likely affects splicing regulatory elements or transcription
factor binding within the first large intron of MAPT.
A 2007 study found that the H1c haplotype specifically increases both the total level of MAPT
transcripts and the proportion containing four microtubule-binding repeat domains (4R tau) |
4R tau isoforms are the predominant component of pathological tau aggregates in PSP, CBD, and some
forms of Alzheimer's disease. This mechanistic finding
directly links the H1c genotype to the molecular pathology of 4R tauopathies: more total tau protein,
with a higher fraction folded into the 4-repeat isoform that aggregates into neurofibrillary tangles
and other tau deposits.
The Evidence
A 2017 meta-analysis of 82 case-control studies found that rs242557 (A allele) confers an odds ratio
of 1.96 (95% CI 1.71–2.25) for PSP and 2.51 (95% CI 1.66–3.78) for CBD | These effect sizes are
among the largest identified for common variants in neurodegenerative disease risk.
The CBD effect size (OR 2.51) is especially striking for a common variant, indicating that H1c
roughly triples the risk of this rare condition compared to non-H1c individuals.
For Alzheimer's disease, the H1c haplotype showed association with AD risk in two autopsy-confirmed
case series (Myers et al., Human Molecular Genetics, 2005) | The AD association appears most relevant
in APOE ε4 non-carriers, where MAPT haplotype becomes a more prominent risk factor.
A 2007 quantitative trait study showed rs242557 drives the H1c association with cerebrospinal fluid
tau levels in a dose-dependent manner (p = 0.002) | Higher CSF tau is a biomarker of neuronal injury
and is elevated years before clinical Alzheimer's onset.
Practical Actions
The H1c genotype does not cause disease on its own — it modifies risk within a multifactorial
landscape. Environmental and lifestyle factors that reduce tau hyperphosphorylation and aggregation
are particularly relevant: avoiding head trauma, controlling metabolic risk factors for neurodegeneration
(blood pressure, insulin resistance), and staying physically and cognitively active. No approved
preventive pharmacotherapy targets tau pathology specifically in the presymptomatic period, but
clinical trials of tau-targeting immunotherapies are ongoing.
Individuals carrying AA or AG genotypes at rs242557 who are also H1/H1 at rs17649553 face the
combined burden of the broad H1 risk and the additional H1c refinement — neurological surveillance
may be warranted if other risk factors (age, family history, additional genetic risk) are present.
Interactions
rs242557 adds independent risk stratification on top of the H1/H2 distinction captured by rs17649553.
Nearly all individuals with the H1c sub-haplotype (A allele at rs242557) are also H1/H1 or H1/H2
at the broader haplotype level — these SNPs are in strong linkage disequilibrium but not perfectly
correlated, so together they provide finer resolution. The rs2471738 variant (also listed among
related SNPs) represents another H1 sub-haplotype marker with comparable effect sizes for PSP
(OR 1.85) and CBD (OR 2.07), and may tag a partially overlapping but distinct risk subgroup.
In Alzheimer's disease, the MAPT H1c effect appears to interact with APOE status: the association
is nominally significant in APOE ε4 carriers but may be more prominent in non-carriers, suggesting
that H1c contributes to a distinct tauopathic path to AD independent of amyloid-driven mechanisms.
All Genotypes
No H1c alleles — baseline PSP and CBD risk within H1 background
You carry two copies of the G allele at rs242557, meaning you do not carry the H1c sub-haplotype of the MAPT gene. Your risk for progressive supranuclear palsy, corticobasal degeneration, and H1c-associated Alzheimer's disease pathology is at baseline for this locus. Approximately 40% of the general population shares this genotype. This result is most informative in the context of your broader MAPT haplotype (rs17649553): if you are H1/H1 at that locus, the absence of H1c means you carry H1 without the highest-risk sub-haplotype. If you carry at least one H2 allele at rs17649553, this result is largely redundant, since H1c only exists on the H1 background.
One H1c allele — moderately elevated PSP and CBD risk
You carry one copy of the A allele at rs242557, tagging one copy of the H1c sub-haplotype. Meta-analytic evidence places the per-allele odds ratio for progressive supranuclear palsy at approximately 1.96 and for corticobasal degeneration at 2.51. As a heterozygote, your risk elevation is intermediate — roughly 1.4- to 1.6-fold above non-carriers depending on the condition. About 47% of the general population carries this genotype. PSP and CBD remain rare diseases (PSP affects approximately 6 per 100,000 people), so this relative risk increase translates to a modest absolute risk increase. The H1c allele also modestly elevates total MAPT expression and the proportion of 4-repeat tau isoforms in brain tissue, which may subtly influence tau biology across the lifespan.
Two H1c alleles — substantially elevated PSP and CBD risk
You carry two copies of the A allele at rs242557, meaning both copies of your MAPT locus carry the H1c sub-haplotype. Meta-analytic data indicate a per-allele odds ratio of approximately 1.96 for PSP and 2.51 for CBD; as a homozygote, your cumulative risk elevation is substantial — roughly 3- to 6-fold above non-carriers for these conditions. About 14% of the general population carries this genotype. It is critical to maintain perspective: PSP affects only about 6 per 100,000 people, so even a 4-fold relative risk increase translates to an absolute lifetime risk well below 1%. The AA genotype is a risk modifier within a multifactorial disease landscape — it does not determine your fate. However, it warrants proactive neurological awareness and lifestyle optimization.